| Old Articles: <Older 3211-3220 Newer> |
|---|
 |
The Motley Fool
October 19, 2006
Brian Lawler |
No Gilded Quarter for Gilead The company's recent acquisition may help it become a diversified drug giant. Investors, take note.   |
The Motley Fool
October 19, 2006
Brian Lawler |
Amylin's One-Drug Wonder Unfortunately, with research and development costs growing to $54 million from $33 million last year, Amylin is still a few quarters away from profitability. Diabetes drug Byetta is set to boost Amylin's sales. Investors, take note. |
The Motley Fool
October 18, 2006
Rich Duprey |
FDA Expands Alzheimer's Treatment Japan's fourth-largest pharmaceutical Eisai's Aricept wins the right to treat all stages of Alzheimer's. Investors, take note. |
The Motley Fool
October 18, 2006
Brian Lawler |
Another Hard Pill to Swallow A former FDA chief will take the fall for not disclosing holdings, but the pharmaceuticals industry needs more than that. |
Bio-IT World
October 2006
John Russell |
Entelos Makes Post IPO Report After netting $16.6 million in a public offering on London's Alternative Investment Market last April, biosimulator Entelos released interim six-month results. |
Bio-IT World
October 2006
Robert M. Frederickson |
Fast Track to Compounds and Crystals Nexus Biosystems' IRORI systems allows synthesis of tens to tens of thousands of compounds. Nexus' Kan Reactors are miniaturized devices that contain both a functionalized solid phase support and a unique tag identifier for the synthesis of a discrete compound. |
Bio-IT World
October 2006
Eric K. Neumann |
The Advantages of a Drug Safety Commons Once a Drug Safety Commons has been established, a variety of derivative applications will be developed that can access as well as update the information in organized ways and used by industry researchers internally. |
Bio-IT World
October 2006
Michael A. Greeley |
What Use Is the $1,000 Genome? Industry is focused on the $1,000 genome -- but investors want to see revenue and profits. The goal of simply reaching the $1,000 genome threshold inherently lacks a business model. What are the applications or products or services that will be unleashed by reaching that milestone? |
Bio-IT World
October 2006
John Russell |
GNS Charts "Unknown" Biology Gene Network Sciences' CEO and colleagues now think they have the right tool to mine the treasure trove of unknown biology hidden in the wealth of accumulating omic data. |
Bio-IT World
October 2006
Mark D. Uehling |
Datasci Suits Threaten Industry The U.S. Patent Office is under scrutiny in a series of lawsuits that are baffling the world of clinical trial technology. |
| <Older 3211-3220 Newer> Return to current articles. |
